Lyell Immunopharma (LYEL) Net Equity Issued and Repurchased (2020 - 2026)

Lyell Immunopharma (LYEL) reported Net Equity Issued and Repurchased of $1.7 million for Q1 2026, up 5239.39% sequentially from -$33000.0 in Q2 2020.

Lyell Immunopharma (LYEL) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Lyell Immunopharma (LYEL) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $1.7 million in Q1 2026.

For the quarter ending Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was $50.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased grew to $1.7 million in Q1 2026, from -$33000.0 in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $1.7 million in Q1 2026 to a low of $1.7 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	141.90 Mn
10	Lyell Immunopharma	298.14 Mn	298.14 Mn	-	1.70 Mn

Download Data